secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001837607-26-000018
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%
--------------------------------------------------------------------------------

- Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.
- FDA BPD Type 2a meeting provided clear framework for remaining analytical comparability program; majority to be completed in 2026.
- Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90%.
- Appointed John Bencich as CFO; cash of $3.0M at Dec 31, 2025 plus $4.2M Jan PIPE proceeds expected to fund ops into Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/0001837607-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/aeon-20260330x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer